U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266402) titled 'A Study of CDX-0159 in Patients With Cold Induced Urticaria and Symptomatic Dermographism' on Nov. 19.
Brief Summary: The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism who remain symptomatic despite the use of H1-antihistamines.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Inducible Urticaria
Cold Urticaria
Cold-Induced Urticaria
Symptomatic Dermographism
Intervention:
DRUG: Barzolvolimab
Subcutaneous Administration
DRUG: ...